Sense of smell in chronic rhinosinusitis: A multicentric study on 811 patients
- Autori: Macchi, Alberto; Giorli, Alessia; Cantone, Elena; Carlotta Pipolo, Giorgia; Arnone, Flavio; Barbone, Umberto; Bertazzoni, Giacomo; Bianchini, Chiara; Ciofalo, Andrea; Cipolla, Federica; De Massimi, Alessio; De Vita, Carla; Di Lieto, Cristina; Ghidini, Angelo; Govoni, Marco; Gramellini, Giulia; Maselli Del Giudice, Alessandro; Ottaviano, Giancarlo; Seccia, Veronica; Sireci, Federico; Sollini, Giacomo; Staffieri, Claudia; Gallo, Stefania; Heffler, Enrico; La Mantia, Ignazio; De Corso, Eugenio; Canevari, Frank Rikki; Lombardo, Nicola; Malvezzi, Luca; Orietti, Gabriele; Pasquini, Ernesto; Presutti, Livio; Monti, Giulia
- Anno di pubblicazione: 2023
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/669424
Abstract
Introduction: The impairment of the sense of smell is often related to chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP, CRSsNP). CRSwNP is a frequent condition that drastically worsens the quality of life of those affected; it has a higher prevalence than CRSsNP. CRSwNP patients experience severe loss of smell with earlier presentation and are more likely to experience recurrence of their symptoms, often requiring revision surgery. Methods: The present study performed a multicentric data collection, enrolling 811 patients with CRS divided according to the inflammatory endotype (Type 2 and non-Type 2). All patients were referred for nasal endoscopy for the assessment of nasal polyposis using nasal polyp score (NPS); Sniffin’ Sticks olfactory test were performed to measure olfactory function, and SNOT-22 (22-item sinonasal outcome test) questionnaire was used to assess patients’ quality of life; allergic status was evaluated with skin prick test and nasal cytology completed the evaluation when available. Results: Data showed that Type 2 inflammation is more common than non-type 2 (656 patients versus 155) and patients suffer from worse quality of life and nasal polyp score. Moreover, 86.1% of patients with Type 2 CRSwNP were affected by a dysfunction of the sense of smell while it involved a lesser percentage of non-Type 2 patients. Indeed, these data give us new information about type-2 inflammation patients’ characteristics. Discussion: The present study confirms that olfactory function weights on patients’ QoL and it represents an important therapeutic goal that can also improve patients’ compliance when achieved. In a future – and present – perspective of rhinological precision medicine, an impairment of the sense of smell could help the clinician to characterize patients better and to choose the best treatment available.